The Archive · 4 posts
Discover EMV Capital PLC! Trusted venture partners delivering innovation in technology and healthcare, traded on LSE. 🚀 #EMVC
EMV Capital's 2025 results show AUM up 14% to £112.5M and losses narrow 83%, but cash remains tight with a going concern warning.
May 19, 2026
Showing 3 of 4 posts
EMV Capital's 2025 update: 16% revenue growth, AUM above £100M, and Venture Building delivers 12.9x returns in a challenging market.
JoshuaFebruary 2, 2026
EMV Capital acquires Destiny Pharma's XF-73 antimicrobial platform for up to £2.475m, paying just £475k upfront with the rest tied to clinical and regulatory success.
JoshuaSeptember 22, 2025
EMV Capital’s 2024 results: 67% revenue growth to £2.5m but losses widen to £3.7m. Analysing the investor’s strategic shift amid portfolio expansion.
JoshuaJune 4, 2025
June 4, 2025